

NHS TAYSIDE COVID-19 NON-HOSPITALISED PATIENT ASSESSMENT FLOW CHART: ELIGIBILITY FOR ANTIVIRALS OR NEUTRALISING MONOCLONAL ANTIBODIES

COVID-19 positive patient triggered
from Public Health data, self-refers or
referred by specialty team

PATIENT MEETS ALL OF THE FOLLOWING CRITERIA:*

1. PCR positive or LFT positive (registered result)
2. Onset of COVID-19 symptoms within last 5 days (extended to 7 days if clinically indicated)
3. Patient showing no signs of clinical recovery
4. Patient in HIGHEST risk group - defined [here](#)
5. On review does not require hospitalisation for COVID-19 management or new supplemental oxygen requirement specifically for management of COVID-19

NOTES:
*Use clinical judgement within MDT (minimum 3 consultants/ pharmacists with experience of managing COVID-19 infection) for conditions/clinical scenarios not listed.

No

Not eligible
for antiviral or
nMAB
outpatient
pathway

Yes

Refer to
paediatric team

Patient
aged <18
years?

No

Patient assessed
as suitable for Paxlovid?
- refer to [assessment
guide](#) and discuss with
pharmacist**

Yes

1st line

Offer patient oral
Paxlovid -
guidance [here](#)

** If pharmacist is not available and patient is nearing end of treatment window consider alternatives

***Only contra-indication is known hypersensitivity to nMAB to be administered. COVID nMABs have no drug interactions. If patient is pregnant, at risk of pregnancy or breastfeeding see information on individual medicine documents and discuss with MDT + Obstetrics Team

****Reasons nMAB administration not possible include: patient unable or does not wish to travel, stock not available, EBAU at capacity, IV access not possible, patient does not wish IV infusion

No

Patient assessed as
suitable for Sotrovimab***
and administration is
possible?****

Yes

Alternative
1st line

Offer patient IV
Sotrovimab -
guidance [here](#)

No

IV administration is
possible but Sotrovimab
not available?

Yes

2nd line

Offer patient IV
Remdesivir
3 day course -
guidance [here](#) -
must be able to
attend EBAU for 3
consecutive days

No

3rd line

Offer patient oral
Molnupiravir -
guidance [here](#)

Note: clinical trial data and relative risk reduction (RRR) of hospitalisation for each treatment available on p3 of clinical guide [link here](#)

Trial populations:
unvaccinated + at least 1 risk
factor for severe Covid

Developed by K Hill/A Shaw
+ Resp/ID/HDU/Lab Team/Primary Care
Approved by: AMG/ADTC Dec 2021
Updated: Feb 2022 (v3)
Review: Ongoing